{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-000811","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2025-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.088447+00:00","generated_at":"2026-05-28T12:31:48.426668+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytoSorbents reports preliminary Q4 product revenue $9.0M-$9.2M, 22-25% YoY growth; full-year ~$35.5M, 14% growth","bullets":["Q4 2024 product revenue est $9.0M-$9.2M, 22-25% YoY growth vs $7.35M in Q4 2023.","Full-year 2024 product revenue est $35.4M-$35.6M, ~14% growth vs $31.1M in FY 2023.","Q4 gross margin est ~70%, up from 61% in Q3 2024, driven by resolution of manufacturing issues.","Rights offering commenced Dec 23, 2024; subscription period ends Jan 10, 2025.","FDA and Health Canada reviews for DrugSorb-ATR marketing application underway; decisions expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-000811","json":"https://secwatch.observer/filing/0001104659-25-000811.json","markdown":"https://secwatch.observer/filing/0001104659-25-000811.md","text":"https://secwatch.observer/filing/0001104659-25-000811.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925000811/0001104659-25-000811-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925000811/tm251882d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T12:31:48.426668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}